Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
Pubmed URL :
https://www.ncbi.nlm.nih.gov/pubmed/PMID: 31285374/
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients.
Pubmed URL :
https://www.ncbi.nlm.nih.gov/pubmed/PMID: 31292534/
Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
Pubmed URL :
https://www.ncbi.nlm.nih.gov/pubmed/PMID: 31028608/
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Pubmed URL :
https://www.ncbi.nlm.nih.gov/pubmed/PMID: 31060539 /
Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer.
A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.
Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions.
Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy.
Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients.
Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX.
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.